European Medicines Agency recommended 104 medicines for approval in 2025
January 20, 2026Research and Development European Medicines Agency, Rare Diseases
The European Medicines Agency (EMA) has announced data from 2025 showing that over the course of the year it recommended …
Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure
January 19, 2026Medical Education Neurology, spinal muscular atrophy
New research from the Centre for Surgery has shown a significant rise in Google searches relating to spinal muscular atrophy …
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
January 19, 2026Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …
Alto Neuroscience announces new patent for depression treatment
January 15, 2026Sales and Marketing Alto Neuroscience, Psychiatry, depression
Alto Neuroscience, a clinical-stage biopharmaceutical company specialising in precision treatments for neuropsychiatric conditions, has announced the issuance of a US …
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
January 15, 2026Sales and Marketing Arkin Capital, biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed to invest in pre-clinical and …
Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
January 14, 2026Research and Development Bio-Sourcing, Oncology, Zerion Pharma, breast cancer
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of the monoclonal antibody trastuzumab for …
Biocartis announces breast cancer research collaboration with US Mayo Clinic
January 14, 2026Research and Development Biocartis, Mayo Clinic, Oncology, breast cancer
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop an accelerated sample-to-answer test resulting …
Blue Earth announces first UK patient received prostate cancer injection
January 13, 2026Research and Development Blue Earth Therapeutics, Oncology, prostate cancer
Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first UK patient has received its …
Medicus Pharma’s Teverelix shows positive efficacy and safety in premenopausal women
January 13, 2026Research and Development Endocrinology, Medicus Pharma, Teverelix
Medicus Pharma’s Teverelix has demonstrated long-lasting hormone suppression, as well as a favourable safety profile, in new study data. Teverelix …
PSI announces new Osaka office as part of Japanese expansion
January 12, 2026Sales and Marketing Osaka, PSI
PSI, a global contract research organisation (CRO), has announced the opening of a new office in Osaka as part of …
Teva’s Ajovy significantly reduces migraine in children and adolescents
January 12, 2026Research and Development Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …
Just – Evotec given Gates Foundation grant to increase global biotherapeutics access
January 8, 2026Research and Development Gates Foundation, Just – Evotec Biologics
Evotec has announced that its subsidiary, Just – Evotec Biologics, has received a Gates Foundation grant with the goal of …
Johnson & Johnson submits robotic surgical system for De Novo classification
January 8, 2026Research and Development FDA, Gastrointestinal tract, Johnson & Johnson
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De Novo classification from the US …
EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan
January 7, 2026Research and Development Psychiatry, ea pharma, schizophrenia
EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical trial of evenamide, a schizophrenia …
Eleva appoints Erich Rajkovic as Chief Business Officer
January 7, 2026Chief Business Officer, Eleva
Eleva, a biopharmaceutical company specialising in formerly inaccessible biologics, has announced the appointment of Dr Erich Rajkovic as Chief Business …
MedPharm announces US FDA inspection of North Carolina manufacturing facility
January 6, 2026Manufacturing and Production FDA, MedPharm
MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful inspection of its topical drug …
Mavatar announces research collaboration with Sobi
January 6, 2026Research and Development Immunology, Mavatar, Rare Diseases, sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …
DemeRx announces completion of alcohol use disorder treatment trial
January 5, 2026Research and Development DemeRx, alcohol use disorder
DemeRx has announced the successful completion of its phase 1 study of DMX-1001 (oral noribogaine) in the treatment of alcohol …
Andera Partners leads financing for asthma treatment company Spiro Medical
January 5, 2026Sales and Marketing Andera Partners, Asthma & COPD, Spiro Medical
Andera Partners, a private equity firm, has announced its leadership of a $67m series A financing round in Spiro Medical, …
STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases
December 18, 2025Research and Development Bio-Thera, Immunology, Stada
STADA and Bio-Thera’s Gotenfia (golimumab), a biosimilar of Janssen’s Simponi, has received a positive opinion from the European Medicines Agency …
Latest content
FibroFind appoints Lee Borthwick as CEO
